LLC "European Medical Alliance", reg.no: 147124109, founded in 2007. The main goals and objectives of our company are the promotion of progressive methods of treatment and drugs. We unite the efforts of many companies and organizations, exchange experience and choose the best. Our colleagues are medical companies from different countries and continents. That's why our company is called Alliance. In the face of the 2020 pandemic, we have refocused and expanded our operations. Particular attention in our activities today is paid to promoting medicines to fight the pandemic and help promote innovative drugs and vaccines for COVID-19. Today our company has reached a new level of cooperation with institutions and foundations from different countries that have joined the difficult fight against the pandemic. In 2020, we completed the first projects, including pre-investment audit and business diagnostics projects, which determined the further development of the company. For ourselves, we have identified the most important, in our opinion, areas: consulting and market access.
We are professional corporate consultants specializing in healthcare, pharmaceutical and medical technology companies. We analyze markets, plan new product launches and support investment decisions in the CIS and Central Asia.
We work in a team with partners from different countries. Each of us is a professional in his field. In each of our projects, we strive to become a trusted advisor rather than just a requestor. One of our advantages is that most of our clients come back to us and recommend us to other companies.
Our office is located in Pomorie (Bulgaria), which allows us to effectively cover the entire region of Central and Eastern Europe, Central Asia, Africa, Latin America and the CIS. We also provide services all over the world.
We provide consulting services in the following key areas:
Consulting (pre-investment audit, business diagnostics, support of M&A transactions, FCPA audit);
Seminars and trainings (exchange of experience, promotion of innovative achievements in medicine, training of personnel of pharmaceutical companies);
Market access (development of a launch plan, audit of the regulatory environment, market assessment and analysis, prescriber, payer and consumer analysis).